Home >> Sports

Maria Sharapova doping admission: What next for the tennis ace and what is meldonium?

Five-time Grand Slam tennis champion Maria Sharapova said on Monday she failed a dope test at the Australian Open, and isn't sure what consequences she'll have to face for her mistake.

Sharapova tested positive for Meldonium, a drug she said she had been taking since 2006 but one that was added to the banned list in 2016.

The World Anti-Doping Agency (WADA) analyzed the sample and returned a positive for meldonium, leading to Sharapova being charged on March 2.

The Russian player said "I had a deficiency in magnesium and a family history of diabetes, and there were signs of diabetes. That is one of the medications, along with others, that I received."

According to the BBC, meldonium is manufactured in Latvia and used in other eastern European nations to treat serious heart problems and aid the circulation of oxygen.

The drug was developed at the Latvian Institute of Organic Synthesis to help prevent ischemia, which is a vascular disease that can lead to tissue death. The drug seems to improve the users' mood and become more active, according to the United States National Library of Medicine.

In 2015, a research project funded, in part, by the Partnership for Clean Competition, was tasked with assessing global athlete usage of meldonium. The drug was also added to the 2015 WADA monitoring program, highlighting that its use was questionable.

Sharapova will be provisionally suspended from March 12, with her actual penalty yet to be decided. She could end up facing a punishment that ranges a minimum sanction with no suspension to a four-year ban.

The updated 2015 WADA code has increased minimum ban for "deliberate cheating" from 2-4 years. But if Sharapova is found to be "doping unintentionally" or "at no significant fault," the suspension period could be as less as one year.